Molecular Mode of Action and Role of TP53 in the Sensitivity to the Novel Epothilone Sagopilone (ZK-EPO) in A549 Non-Small Cell Lung Cancer Cells

• Sebastian Winsel,

  Affiliations Global Drug Discovery, Bayer Healthcare, Berlin, Germany, Institute for Chemistry-Biochemistry, Freie Universität Berlin, Berlin, Germany, Medical Biotechnology, VTT Technical Research Centre of Finland, Turku, Finland

  ⨯
• Anette Sommer,

  Affiliation Global Drug Discovery, Bayer Healthcare, Berlin, Germany

  ⨯
• Julia Eschenbrenner,

  Affiliations Global Drug Discovery, Bayer Healthcare, Berlin, Germany, Institut für Biotechnologie, Technische Universität Berlin, Berlin, Germany

  ⨯
• Kevin Mittelstaedt,

  Affiliations Global Drug Discovery, Bayer Healthcare, Berlin, Germany, Department of Medicine, The University of Melbourne, Melbourne, Australia

  ⨯
• Ulrich Klar,

  Affiliation Global Drug Discovery, Bayer Healthcare, Berlin, Germany

  ⨯
• Stefanie Hammer ,

  * E-mail: stefanie.hammer@bayer.com (SH); jens.hoffmann@mdc-berlin.de (JH)

  Affiliation Global Drug Discovery, Bayer Healthcare, Berlin, Germany

  ⨯
• Jens Hoffmann

  * E-mail: stefanie.hammer@bayer.com (SH); jens.hoffmann@mdc-berlin.de (JH)

  Affiliations Global Drug Discovery, Bayer Healthcare, Berlin, Germany, Experimental Pharmacology, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany

  ⨯